ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1769

Affinity Purification and Characterisation of Anti-CCP Antibodies From Plasma and Synovial Fluids of Patients with Rheumatoid Arthritis

Elena Ossipova1, Catia Cerqueira2, Evan Reed2, Nastya Kharlamova2, Lena Israelsson2, Rikard Holmdahl3, Anca Catrina2, Vivianne Malmström2, Yngve Sommarin4, Lars Klareskog2, Per Johan Jakobsson2 and Karin Lundberg2, 1Rheumatology unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, Sweden, 4Euro-Diagnostica AB, Malmö, Sweden

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-CCP antibodies, Anti-citrullinated protein/peptide antibodies (ACPA) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: B-cell Biology and Targets in Autoimmune Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Autoimmunity in rheumatoid arthritis (RA) is characterized by autoantibodies to citrullinated proteins/peptides (ACPA). These antibodies (present in 60-70% of patients) antedate clinical onset and associate with an erosive disease course, suggesting a direct pathogenic involvement in disease initiation and progression. With this study, we aimed to utilise plasma and synovial fluids (SF) from patients with RA, for the purification of ACPAs reactive with the peptides used in the CCP2 ELISA assay. Furthermore, to characterise their frequency in plasma and SF as well as reactivity with different autoantigen-derived peptides.

Methods: Plasma (n=16) and SF (n=26) samples were collected, with informed consent and ethical approval, from RA patients with anti-CCP2 IgG levels above 300AU/ml. Total IgG was isolated on Protein G columns, and subsequently applied to CCP2 affinity columns, kindly donated by EuroDiagnostica. Flow through and eluate fractions were assayed for antibody responses using the CCP2 ELISA, as well as in-house ELISAs, for analysis of reactivity to citrullinated peptides from a-enolase, vimentin, fibrinogen and collagen type II.

Results: Pure and intact anti-CCP IgG antibodies were efficiently isolated from plasma and SF samples. No citrulline-reactivity was detected in the CCP2 column flow through fractions. Purified anti-CCP IgG from different patients showed differences in binding to CCP2 ELISA plates (assayed at the same antibody concentration), still a majority showed reactivity with the four citrullinated autoantigen-derived peptides. Purified anti-CCP IgG also bound citrullinated, but not uncitrullinated, human fibrinogen, by Western blot, while the corresponding CCP2 column flow through IgG bound neither citrullinated nor uncitrullinated fibrinogen. A median of 1.5% of the IgG pool in plasma and 2.2% in SF, with four SF samples reaching 6%, were CCP2-reactive.

Conclusion: Here we demonstrate an efficient and robust method to isolate anti-CCP IgG from plasma and SF. Furthermore, that ACPAs reactive with epitopes on different citrullinated autoantigens (i.e. a-enolase, vimentin, fibrinogen and collagen type II), which are largely non-cross-reactive, are captured by the CCP2 column. These purified anti-CCP IgG molecules will provide us with new opportunities to investigate functional and structural aspects of human anti-citrullinated protein/peptide antibodies, including pathogenicity.


Disclosure:

E. Ossipova,
None;

C. Cerqueira,
None;

E. Reed,
None;

N. Kharlamova,
None;

L. Israelsson,
None;

R. Holmdahl,
None;

A. Catrina,
None;

V. Malmström,
None;

Y. Sommarin,
None;

L. Klareskog,
None;

P. J. Jakobsson,
None;

K. Lundberg,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/affinity-purification-and-characterisation-of-anti-ccp-antibodies-from-plasma-and-synovial-fluids-of-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology